TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Alterity Therapeutics ( (ATHE) ) is now available.
On July 7, 2025, Alterity Therapeutics Limited announced a change in substantial holding, with The Bank of New York Mellon Corporation (BNYMC) increasing its voting power in the company from 27.03% to 28.04%. This change in shareholding indicates a growing interest and potential influence of BNYMC in Alterity Therapeutics, which could impact the company’s strategic decisions and stakeholder dynamics.
The most recent analyst rating on (ATHE) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the ATHE Stock Forecast page.
Spark’s Take on ATHE Stock
According to Spark, TipRanks’ AI Analyst, ATHE is a Neutral.
Alterity Therapeutics faces considerable financial challenges, underscored by declining revenues, ongoing losses, and negative cash flows. Technical analysis provides some support, but the valuation remains unattractive due to negative profitability metrics. Overall, the stock score reflects these significant financial and valuation concerns.
To see Spark’s full report on ATHE stock, click here.
More about Alterity Therapeutics
Alterity Therapeutics Limited is a development stage enterprise in the biotechnology industry, focusing on the development of therapies for neurodegenerative diseases.
Average Trading Volume: 44,024
Technical Sentiment Signal: Buy
Current Market Cap: $59.6M
For detailed information about ATHE stock, go to TipRanks’ Stock Analysis page.